특별시의 January 2023 earnings haven't demonstrated Precision Medicine's potential amidst the challenges of 2022 including the Jurong Carson scandal investigation that caused collaboration pauses and pandemic-led clinical trial slowdowns. Yet the stock should gain slightly in the short term following adequate Q4 earnings and leaps in cancer treatment developments.
[1]